10 results on '"Anthony Ragheb"'
Search Results
2. Worsening of Functional Mitral Regurgitation from Septal Dyssynchrony Induced by Ventricular Pacing in Ebstein's Anomaly Undergoing Percutaneous Mitral Valve Repair
- Author
-
Heajung L. Nguyen, Abdulfattah Saidi, Anwar Tandar, Elisa Rhee, András Bratincsák, William Van Alstine, Lindsay Koren, Kimberly Stoughton, José Negrón-Garcia, Anthony Ragheb, Hannah El-Sabrout, John W. Moore, Howaida el-Said, John P. Breinholt, Jason P. Glotzbach, Frederick G.P. Welt, Vikas Sharma, Kelsee Browning, Craig H. Selzman, David A. Bull, Holly Carveth, Marcella A. Calfon Press, Jamil A. Aboulhosn, Jeannette P. Lin, Peyman Benharash, and Eric H. Yang
- Subjects
medicine.medical_specialty ,business.industry ,Ebstein's anomaly ,Internal medicine ,Cardiology ,Medicine ,Ventricular pacing ,business ,medicine.disease ,Functional mitral regurgitation ,Percutaneous Mitral Valve Repair - Abstract
Author(s): Nguyen, Heajung L; Calfon Press, Marcella A; Aboulhosn, Jamil A; Lin, Jeannette P; Benharash, Peyman; Yang, Eric H
- Published
- 2017
3. Improvement in Pulmonary Function After Closure of Atrial Septal Defect in a Patient With Cystic Fibrosis
- Author
-
Abdulfattah Saidi, Anwar Tandar, Elisa Rhee, András Bratincsák, William Van Alstine, Lindsay Koren, Kimberly Stoughton, José Negrón-Garcia, Anthony Ragheb, Hannah El-Sabrout, John W. Moore, Howaida el-Said, John P. Breinholt, Jason P. Glotzbach, Frederick G.P. Welt, Vikas Sharma, Kelsee Browning, Craig H. Selzman, David A. Bull, and Holly Carveth
- Subjects
medicine.medical_specialty ,business.industry ,Closure (topology) ,Medicine ,business ,medicine.disease ,Cystic fibrosis ,Pulmonary function testing ,Surgery - Published
- 2017
4. Successful First-in-Man Concomitant Transapical Transcatheter Aortic and Mitral Valve Replacements for Severe Native Aortic and Mitral Valve Stenosis Using the Edwards Certitude Delivery System
- Author
-
Lindsay Koren, Vikas Sharma, William G. Van Alstine, José Negrón-Garcia, Anthony Ragheb, Frederick G.P. Welt, Jason P. Glotzbach, Elisa Rhee, Howaida El-Said, Hannah El-Sabrout, John P. Breinholt, Anwar Tandar, John W. Moore, Kimberly Stoughton, Abdulfattah Saidi, Kelsee Browning, Andras Bratincsak, Craig H. Selzman, and David A. Bull
- Subjects
medicine.medical_specialty ,medicine.anatomical_structure ,Mitral valve stenosis ,Transcatheter aortic ,business.industry ,Internal medicine ,Mitral valve ,Concomitant ,Cardiology ,Medicine ,Delivery system ,business ,medicine.disease - Published
- 2017
5. Vascular Response of a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) versus a Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) in Healthy Swine Femoropopliteal Arteries
- Author
-
Neel Gadhoke, Raquel Fernandez, Ka Hyun Paek, Daniela T. Fuller, Renu Virmani, Hiroyuki Jinnouchi, Kenji Kawai, Yu Sato, Rika Kawakami, Salomé Kuntz, Aloke V. Finn, Frank D. Kolodgie, Sho Torii, Liang Guo, Anne Cornelissen, Anthony Ragheb, Masayuki Mori, Brandt Young, and Atsushi Sakamoto
- Subjects
Neointima ,medicine.medical_specialty ,Time Factors ,Paclitaxel ,Polymers ,Swine ,medicine.medical_treatment ,Urology ,Lumen (anatomy) ,Vascular Remodeling ,Prosthesis Design ,Fibrin ,Aneurysm ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,Wound Healing ,biology ,business.industry ,Endovascular Procedures ,Stent ,Cardiovascular Agents ,Drug-Eluting Stents ,Internal elastic lamina ,medicine.disease ,Femoral Artery ,body regions ,Stenosis ,Drug-eluting stent ,biology.protein ,Swine, Miniature ,Cardiology and Cardiovascular Medicine ,business ,human activities - Abstract
Purpose To compare the long-term vascular healing responses of healthy swine iliofemoral arteries treated with a polymer-free paclitaxel-eluting stent (Z-PES, Zilver PTX) or a fluoropolymer-based paclitaxel-eluting stent (FP-PES, Eluvia). Materials and Methods Bilateral iliofemoral arteries in 20 swine were treated with a Z-PES (n = 16) or a FP-PES (n = 24) and were examined histologically at 1, 3, 6, and 12 months. Results Morphometric analysis revealed larger external and internal elastic lamina, stent expansion, and lumen area in the FP-PES than in the Z-PES at all timepoints. Luminal narrowing was similar in the 2 groups at 1 month; however, greater stenosis was observed in the Z-PES group at 3 months, with significant regression thereafter, resulting in equivalent stenosis at 6 and 12 months. Greater drug effect and less complete vessel healing were found in the FP-PES group at all timepoints, including greater numbers of malapposed struts with excessive fibrin deposition at 1 and 3 months, than in the Z-PES group. Three of 12 FP-PESs from the 6- and 12-month cohorts also showed circumferential medial disruption with peri-strut inflammation, whereas no abnormal findings were observed in contralateral Z-PESs. Conclusions Prolonged paclitaxel release with the presence of a permanent polymer may contribute to the differential vascular responses seen for the Z-PES and FP-PES groups, including medial layer disruption and aneurysmal vessel degeneration that was sometimes observed in the FP-PES group. These distinct features should be confirmed by pathology and in vivo imaging of human superficial femoral arteries to determine their clinical significance.
- Published
- 2021
6. Safety of Zilver PTX Drug-Eluting Stent Implantation Following Drug-Coated Balloon Dilation in a Healthy Swine Model
- Author
-
Maria Romero, Brandt Young, Kazuyuki Yahagi, Renu Virmani, Emanuel Harari, Anthony Ragheb, Frank D. Kolodgie, Aloke V. Finn, Hiroyoshi Mori, and Sho Torii
- Subjects
medicine.medical_specialty ,Drug coated balloon ,Time Factors ,Swine ,medicine.medical_treatment ,Constriction, Pathologic ,030204 cardiovascular system & hematology ,Balloon ,Prosthesis Design ,Iliac Artery ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Animal model ,Coated Materials, Biocompatible ,Angioplasty ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,business.industry ,Cardiovascular Agents ,Drug-Eluting Stents ,Surgery ,Femoral Artery ,Drug-eluting stent ,Models, Animal ,Dilation (morphology) ,Swine, Miniature ,Cardiology and Cardiovascular Medicine ,business ,Angioplasty, Balloon ,Vascular Access Devices - Abstract
Purpose: To compare the safety of Zilver PTX drug-eluting stents (DES) following drug-coated balloon (DCB) angioplasty or conventional balloon angioplasty (BA) in a healthy porcine iliofemoral artery model. Methods: DES implantation following DCB (DCB+DES) or BA (BA+DES) was assessed by angiography and histology in the nondiseased iliofemoral arteries of 20 animals, with sacrifice at 1, 3, and 6 months. Safety assessment compared quantitative measures of vessel integrity (eg, preservation of artery geometry, structure, and lumen dimensions; absence of aneurysm; malapposition) and histological parameters (eg, excessive inflammation). The percentage of uncovered struts could not be >30% per section and the endothelial cell loss had to be
- Published
- 2017
7. Biologic Drug Effect and Particulate Embolization of Drug-Eluting Stents versus Drug-Coated Balloons in Healthy Swine Femoropopliteal Arteries
- Author
-
Maria Romero, Kazuyuki Yahagi, Brandt Young, Frank D. Kolodgie, Emanuel Harari, Anthony Ragheb, Sho Torii, Renu Virmani, Hiroyoshi Mori, and Aloke V. Finn
- Subjects
Bare-metal stent ,Drug ,medicine.medical_specialty ,Time Factors ,Percutaneous ,Paclitaxel ,medicine.medical_treatment ,media_common.quotation_subject ,Myocytes, Smooth Muscle ,Sus scrofa ,Urology ,030204 cardiovascular system & hematology ,Muscle, Smooth, Vascular ,Fibrin ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Coated Materials, Biocompatible ,Neointima ,medicine ,Animals ,Popliteal Artery ,Radiology, Nuclear Medicine and imaging ,Embolization ,Fibrinoid necrosis ,Muscle, Skeletal ,media_common ,biology ,business.industry ,Skeletal muscle ,Cardiovascular Agents ,Drug-Eluting Stents ,medicine.disease ,Femoral Artery ,medicine.anatomical_structure ,chemistry ,Models, Animal ,biology.protein ,Proteoglycans ,Cardiology and Cardiovascular Medicine ,business ,Angioplasty, Balloon ,Vascular Access Devices - Abstract
Purpose To compare the drug effect in treated vessels and downstream effects in distal skeletal muscle of drug-coated balloons (DCBs) and drug-eluting stents (DESs) in a healthy preclinical swine model. Materials and Methods Four groups of treated iliofemoral arteries (percutaneous transluminal angioplasty [PTA]+DES, DCB+DES, DCB+bare metal stent [BMS], and DCB alone) of 12 healthy swine were assessed, with euthanasia at 30 days. Biological drug effect was evaluated using smooth muscle cell (SMC) loss score according to both depth and circumference as well as a neointimal fibrin and medial proteoglycan scores which were compared between the 4 groups. Vascular and skeletal muscle changes in regions downstream from the treated site were also assessed histologically for evidence of emboli. Results DESs showed greater medial SMC loss in the treated arteries irrespective of preceding DCB or PTA treatment in terms of depth (DCB+DES vs PTA+DES vs DCB+BMS vs DCB alone; median, 4.0 mm vs 3.8 mm vs 3.0 mm vs 2.2 mm; P = .009) and circumference (4.0 mm vs 3.5 mm vs 2.0 mm vs 1.2 mm, respectively; P = .007). Sections of skeletal muscles downstream from the treated arteries showed arteriolar changes of fibrinoid necrosis consistent with paclitaxel effect exclusively in the DCB groups (DCB+BMS, 26.9% of sections; DCB+DES, 14.3%; DCB alone, 19.2%; PTA+DES, 0%; P = .02). Conclusions In the treated arteries, irrespective of preceding DCB treatment or PTA, DES treatment showed maximum drug effects vs DCB alone or in combination with BMS placement, and there was no detrimental toxic effect in DCB-treated iliofemoral arteries before DES treatment compared with PTA before DES treatment. Downstream vascular changes were exclusively seen in groups treated with DCBs.
- Published
- 2018
8. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
- Author
-
Michael R. Jaff, Takao Ohki, Michael D. Dake, Scott A. Snyder, Richard R. Saxon, H. Bob Smouse, Thomas Zeller, Anthony Ragheb, Lindsay S. Machan, Erin E. O’Leary, and Gary M. Ansel
- Subjects
Male ,medicine.medical_treatment ,Femoral artery ,030204 cardiovascular system & hematology ,Vascular Medicine ,Corrections ,law.invention ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,law ,Ischemia ,Recurrence ,Medicine ,Popliteal Artery ,030212 general & internal medicine ,Drug-Eluting Stents ,Middle Aged ,Combined Modality Therapy ,Clopidogrel ,Femoral Artery ,Treatment Outcome ,Paclitaxel ,Disease Progression ,Equipment Failure ,Female ,Stents ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,medicine.drug ,Adult ,medicine.medical_specialty ,Ticlopidine ,Arterial Occlusive Diseases ,peripheral artery disease ,Disease-Free Survival ,03 medical and health sciences ,Physiology (medical) ,medicine.artery ,Angioplasty ,Humans ,Vascular Patency ,Aged ,Aspirin ,business.industry ,Stent ,Anticoagulants ,Original Articles ,Intermittent Claudication ,Popliteal artery ,Intermittent claudication ,Surgery ,chemistry ,business ,Angioplasty, Balloon ,Follow-Up Studies - Abstract
Background— This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus standard care (PTA and provisional Zilver bare metal stent [BMS]), and provisional DES versus provisional BMS. Methods and Results— Patients with symptomatic femoropopliteal artery disease were randomly assigned to DES (n=236) or PTA (n=238). Approximately 91% had claudication; 9% had critical limb ischemia. Patients experiencing acute PTA failure underwent secondary randomization to provisional BMS (n=59) or DES (n=61). The 1-year primary end points of event-free survival and patency showed superiority of primary DES in comparison with PTA; these results were sustained through 5 years. Clinical benefit (freedom from persistent or worsening symptoms of ischemia; 79.8% versus 59.3%, P P P P =0.02), patency (72.4% versus 53.0%, P =0.03), and freedom from target lesion revascularization (84.9% versus 71.6%, P =0.06) with provisional DES were improved over provisional BMS. These results represent >40% relative risk reduction for restenosis and target lesion revascularization through 5 years for the overall DES in comparison with standard care and for provisional DES in comparison with provisional BMS. Conclusions— The 5-year results from this large study provide long-term information previously unavailable regarding endovascular treatment of femoropopliteal artery disease. The Zilver PTX DES provided sustained safety and clinical durability in comparison with standard endovascular treatments. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00120406.
- Published
- 2015
9. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials
- Author
-
Scott A. Snyder, Michael R. Jaff, Takao Ohki, Hiroyoshi Yokoi, Kimihiko Kichikawa, Takeshi Kimura, Michael D. Dake, Gary M. Ansel, Erin E. O’Leary, and Anthony Ragheb
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Paclitaxel ,medicine.medical_treatment ,Subgroup analysis ,Constriction, Pathologic ,Kaplan-Meier Estimate ,Prosthesis Design ,Disease-Free Survival ,law.invention ,Peripheral Arterial Disease ,Randomized controlled trial ,Japan ,law ,medicine.artery ,Germany ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Popliteal Artery ,Prospective Studies ,Vascular Patency ,Aged ,Aged, 80 and over ,business.industry ,Superficial femoral artery ,Reproducibility of Results ,Cardiovascular Agents ,Drug-Eluting Stents ,Middle Aged ,medicine.disease ,Limb Salvage ,Popliteal artery ,United States ,Surgery ,Prosthesis Failure ,Clinical trial ,Femoral Artery ,Stenosis ,Treatment Outcome ,Drug-eluting stent ,Research Design ,Cohort ,Female ,Cardiology and Cardiovascular Medicine ,business ,Angioplasty, Balloon - Abstract
To report a subgroup analysis comparing safety and effectiveness outcomes in Japanese and non-Japanese patients as part of a prospective, multinational, randomized controlled trial (ClinicalTrials.gov identifier NCT00120406) evaluating a paclitaxel-coated drug-eluting stent (DES) compared to percutaneous transluminal angioplasty (PTA) for treating peripheral artery disease.Patients were randomly assigned to primary DES or PTA. In the Japanese cohort, 27 patients (21 men; mean age 71.2±9.6 years) were randomized to PTA and 25 patients (19 men; mean age 69.8±10.2 years) to primary DES. In the non-Japanese cohort, 211 patients (131 men; mean age 67.3±10.6 years) were randomized to PTA and 211 patients (136 men; mean age 67.6±9.5 years) to primary DES. Outcome measures included event-free survival (EFS), freedom from target lesion revascularization (TLR), patency, stent fracture, and sustained clinical benefit through 2 years.Safety and effectiveness outcomes were similar in the Japanese and non-Japanese cohorts, although the outcomes in the Japanese cohort treated with primary DES were numerically better. In the DES group, the 2-year EFS was 92.0% vs. 85.0% (p=0.61), freedom from TLR was 96.0% vs. 85.5% (p=0.55), primary patency was 80.0% vs. 74.3% (p=0.61), and clinical benefit was sustained in 88.5% vs. 80.5% of patients (p=0.31) in the Japanese and non-Japanese cohorts, respectively. Stent fractures were seen in 4 of 457 stents at 12 months: 3 in the Japanese cohort and 1 in the non-Japanese cohort.The subgroup analysis comparing Japanese and non-Japanese patients supports the safety and effectiveness of the paclitaxel-coated DES in Japanese patients with stenotic lesions in the femoropopliteal arteries. The lack of major differences associated with ethnicity in these 2-year outcomes supports the validity and value of multinational clinical trials.
- Published
- 2014
10. Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries
- Author
-
Michael D. Dake, Anthony Ragheb, Qing Zhou, and William G. Van Alstine
- Subjects
Male ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,Sus scrofa ,Comparative safety ,Polymer free ,Prosthesis Design ,Risk Assessment ,chemistry.chemical_compound ,Pharmacokinetics ,Coated Materials, Biocompatible ,Internal medicine ,Materials Testing ,medicine ,Alloys ,Animals ,Radiology, Nuclear Medicine and imaging ,Adverse effect ,Wound Healing ,Hematology ,business.industry ,Stent ,Cardiovascular Agents ,Drug-Eluting Stents ,Arteries ,Surgery ,medicine.anatomical_structure ,chemistry ,Models, Animal ,Female ,Cardiology and Cardiovascular Medicine ,business ,Artery - Abstract
Purpose To evaluate the pharmacokinetics and safety of the Zilver PTX Drug-Eluting Stent (Cook Medical, Bloomington, Indiana) in a normal porcine artery model. Materials and Methods Pharmacokinetic analyses were performed using 18 pigs, each implanted with four paclitaxel-coated stents. Paclitaxel remaining on the stents, delivered locally (to artery wall), regionally (to adjacent and downstream muscle), and systemically (to plasma), was determined at various times through 56 days. For safety evaluation, local, regional, and systemic responses were grossly and histologically assessed at 1 month, 3 months, and 6 months in 21 additional pigs and compared with the responses to bare metal stents in 21 separate pigs. Results Stents delivered approximately 95% of the total paclitaxel within 24 hours after deployment. Nonetheless, there were sustained paclitaxel levels in the artery wall through 56 days, maintained at approximately 20% of the peak level through 14 days. Very little paclitaxel was distributed regionally or systemically, becoming undetectable in plasma at 10 hours. Complete necropsy, hematology, and serum chemistry revealed no adverse effects associated with the paclitaxel-coated stents. Within 3 months, vessels with both paclitaxel-coated and bare metal stents showed comparable, complete healing. Conclusions The Zilver PTX stent appears to be safe, achieves sustained paclitaxel levels in the artery wall, and shows complete vessel healing comparable to bare metal stents within 3 months.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.